» Articles » PMID: 23585946

Thymic Neoplasm: a Rare Disease with a Complex Clinical Presentation

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2013 Apr 16
PMID 23585946
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Thymic neoplasms constitute a broad category of rare lesions with a wide spectrum of pathologic characteristics and clinical presentations which therefore require a high index of suspicion to diagnose. The natural history of the disease is seldom predictable, anywhere from an indolent to an aggressively malignant course. Although the classification and staging of these lesions are complex and controversial, complete radical surgical resection remains the gold standard of therapy. Radiation and chemotherapy are important elements of the multimodality approach to treating these patients and it is important for thoracic surgeons to work closely with their colleagues in other disciplines in the management of and future research endeavors in thymic neoplasm. In this review, we discuss the evaluation of the patient with an anterior mediastinal mass, the classification and staging of thymic neoplasms, the role of surgery, radiation and chemotherapy in treating this disease, as well as future directions in research for novel targeted therapies.

Citing Articles

Metabolic signatures of thymomas: potential biomarkers and treatment targets.

Miller J, Faubert B, Mathews T, Waters J, DeBerardinis R, Kernstine K Eur J Cardiothorac Surg. 2023; 65(2).

PMID: 38011656 PMC: 10882262. DOI: 10.1093/ejcts/ezad394.


Unraveling the Role of Histone Variant CENP-A and Chaperone HJURP Expression in Thymic Epithelial Neoplasms.

Levidou G, Palamaris K, Sykaras A, Andreadakis G, Masaoutis C, Theochari I Int J Mol Sci. 2022; 23(15).

PMID: 35955489 PMC: 9368969. DOI: 10.3390/ijms23158339.


Ephrin Receptors (Ephs) Expression in Thymic Epithelial Tumors: Prognostic Implications and Future Therapeutic Approaches.

Masaoutis C, Georgantzoglou N, Sarantis P, Theochari I, Tsoukalas N, Bobos M Diagnostics (Basel). 2021; 11(12).

PMID: 34943502 PMC: 8700455. DOI: 10.3390/diagnostics11122265.


Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series.

Salas P, Solovera M, Bannura F, Munoz-Medel M, Cordova-Delgado M, Sanchez C Ecancermedicalscience. 2021; 15:1201.

PMID: 33889210 PMC: 8043676. DOI: 10.3332/ecancer.2021.1201.


Thymic epithelial tumors: Do we know all the prognostic factors?.

Knetki-Wroblewska M, Kowalski D, Olszyna-Serementa M, Krzakowski M, Szolkowska M Thorac Cancer. 2021; 12(3):339-348.

PMID: 33386778 PMC: 7862797. DOI: 10.1111/1759-7714.13750.


References
1.
Kosmidis P, Iliopoulos E, Pentea S . Combination chemotherapy with cyclophosphamide, adriamycin, and vincristine in malignant thymoma and myasthenia gravis. Cancer. 1988; 61(9):1736-40. DOI: 10.1002/1097-0142(19880501)61:9<1736::aid-cncr2820610903>3.0.co;2-t. View

2.
Barth T, Leithauser F, Joos S, Bentz M, Moller P . Mediastinal (thymic) large B-cell lymphoma: where do we stand?. Lancet Oncol. 2002; 3(4):229-34. DOI: 10.1016/s1470-2045(02)00714-3. View

3.
Lewis J, Wick M, Scheithauer B, BERNATZ P, Taylor W . Thymoma. A clinicopathologic review. Cancer. 1987; 60(11):2727-43. DOI: 10.1002/1097-0142(19871201)60:11<2727::aid-cncr2820601125>3.0.co;2-d. View

4.
Gomez D, Komaki R . Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol. 2010; 5(10 Suppl 4):S336-43. DOI: 10.1097/JTO.0b013e3181f20ea2. View

5.
Marom E . Imaging thymoma. J Thorac Oncol. 2010; 5(10 Suppl 4):S296-303. DOI: 10.1097/JTO.0b013e3181f209ca. View